CV

CapsoVision, Inc. Common Stock
CV
Market cap $187M

3.99 USD

+0.00

0.00%

Updated Aug 26, 11:45 AM EDT

1 day

0.00%

5 days

2.84%

1 month

-8.28%

3 months

14.00%

6 months

14.00%

Year to date

14.00%

1 year

14.00%

5 years

14.00%

10 years

14.00%

About: CapsoVision Inc is a commercial-stage medical technology enterprise, innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company's core technology platform is an orally ingestable capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. The Company's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D directed at the large intestines.

Healthcare Medical Devices

–

Funds holding %

of 7,431 funds

–

Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$5

25%

upside

Avg. target

$5

25%

upside

High target

$5

25%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Benchmark

Bruce Jackson

25%upside

$5

Speculative Buy

Initiated

28 Jul 2025

See Analyst Rankings

Financial journalist opinion

CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025

- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market.

CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025

CapsoVision Announces Closing of Initial Public Offering

SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.”

CapsoVision Announces Closing of Initial Public Offering

CapsoVision Announces Pricing of Initial Public Offering

SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.” The offering is expected to close on July 3, 2025 subject to the satisfaction of customary closing conditions.

CapsoVision Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: Consumer Collections Firm Leads 4 IPO Week, As Two Billion Dollar Listings Join The Pipeline

Four IPOs and five SPACs debuted this week. Four IPOs and two SPACs submitted initial filings this week. The July IPO market is slated for a quiet start, with just a couple IPOs scheduled for the short Fourth of July week ahead.

U.S. IPO Weekly Recap: Consumer Collections Firm Leads 4 IPO Week, As Two Billion Dollar Listings Join The Pipeline

CapsoVision Proposes IPO Terms For GI Tract Imaging Capsule Technology

CapsoVision, Inc. is seeking $27.6M in an IPO, but faces slowing revenue growth, high losses, and minimal operating capital. CapsoVision's valuation expectations are excessive, with an 18x EV/Revenue multiple versus industry norms, despite flattening topline growth. Financials show rising operating losses, negative free cash flow, and declining marketing efficiency, raising concerns about sustainability.

CapsoVision Proposes IPO Terms For GI Tract Imaging Capsule Technology

See News Rankings

Charts implemented using Lightweight Charts™